| Achillion Pharmaceuticals is a biopharmaceutical company. Co. is engaged in the discovery and development of small molecule drug therapies for immune system disorders. Co. is advancing orally administered small molecules from its platform that target complement factor D, an essential protein of the alternative pathway. The alternative pathway plays a role in a number of disease conditions, including therapeutic areas of nephrology, hematology, ophthalmology and neurology. Initially Co. is targeting C3 glomerulopathy, and immune complex membranoproliferative glomerulonephritis, two related rare diseases affecting the kidney, and paroxysmal nocturnal hemoglobinuria, a blood disorder. We show 39 historical shares outstanding datapoints in our coverage of ACHN's shares outstanding history.|
Understanding the changing numbers of ACHN shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACHN versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACHN by allowing them to research ACHN shares outstanding history
as well as any other stock in our coverage universe.